At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
SCNX Scienture Holdings, Inc.
Post-Mkt 08-19 17:01:57 EDT
0.4741
+0.0172
+3.76%
盘后0.4580
-0.0161-3.40%
17:01 EDT
High0.4800Low0.4308Vol662.08K
Open0.4600D1 Closing0.4569Amplitude10.77%
Mkt Cap19.47MTradable Cap16.08MTotal Shares41.06M
T/O306.21KT/O Rate1.95%Tradable Shares33.92M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Scienture Holdings Q2 EPS $(0.07) Beats $(0.08) Estimate, Sales $343.639K Miss $1.964M Estimate
Benzinga Earnings  ·  08-14
Scienture Holdings Q2 EPS $(0.07) Beats $(0.08) Estimate, Sales $343.639K Miss $1.964M Estimate
Scienture Q2 Revenue Surges on Rezenopy Launch
Reuters  ·  08-14
Scienture Q2 Revenue Surges on Rezenopy Launch
Scienture Holdings, Inc Q2 Operating Expenses USD 3 Million
THOMSON REUTERS  ·  08-14
Scienture Holdings, Inc Q2 Operating Expenses USD 3 Million
Scienture Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance
THOMSON REUTERS  ·  08-14
Scienture Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance
Scienture Holdings Inc Reports Results for the Quarter Ended June 30 - Earnings Summary
Reuters  ·  08-14
Scienture Holdings Inc Reports Results for the Quarter Ended June 30 - Earnings Summary
Scienture Net Loss Narrows to $2.82 Million in Q2 FY26; Revenue Turns to $343,639
Reuters  ·  08-14
Scienture Net Loss Narrows to $2.82 Million in Q2 FY26; Revenue Turns to $343,639
Scienture Announces Commercial Launch and Fulfillment of Initial Purchase Orders of Rezenopy™, the Highest Dose FDA-Approved Naloxone Nasal Spray
THOMSON REUTERS  ·  08-12
Scienture Announces Commercial Launch and Fulfillment of Initial Purchase Orders of Rezenopy™, the Highest Dose FDA-Approved Naloxone Nasal Spray
Scienture Holdings Inc Expected to Post a Loss of 23 Cents a Share - Earnings Preview
Reuters  ·  08-07
Scienture Holdings Inc Expected to Post a Loss of 23 Cents a Share - Earnings Preview
When Will Scienture Holdings, Inc. (NASDAQ:SCNX) Become Profitable?
Simply Wall St.  ·  07-27
When Will Scienture Holdings, Inc. (NASDAQ:SCNX) Become Profitable?
Analysts Are Bullish on Top Healthcare Stocks: Scienture Holdings (SCNX), Royalty Pharma (RPRX)
TIPRANKS  ·  07-10
Analysts Are Bullish on Top Healthcare Stocks: Scienture Holdings (SCNX), Royalty Pharma (RPRX)
Scienture Holdings Stock Jumps Over 20% Pre-Market: Here's Why
Benzinga  ·  07-10
Scienture Holdings Stock Jumps Over 20% Pre-Market: Here's Why
Scienture to begin shipments of Rezonopy to wholesalers
TIPRANKS  ·  07-09
Scienture to begin shipments of Rezonopy to wholesalers
Scienture Holdings - to Begin July Shipments of Rezenopy Nasal Spray 10 Mg to U.S. Wholesalers
THOMSON REUTERS  ·  07-09
Scienture Holdings - to Begin July Shipments of Rezenopy Nasal Spray 10 Mg to U.S. Wholesalers
SCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY™ (naloxone hydrochloride) to Wholesalers
GlobeNewswire  ·  07-09
SCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY™ (naloxone hydrochloride) to Wholesalers
Scienture announces progress in commercialization of Arbli
TIPRANKS  ·  06-18
Scienture announces progress in commercialization of Arbli
Scienture says large national health plan adds REZENOPY naloxone spray to formulary
Reuters  ·  06-09
Scienture says large national health plan adds REZENOPY naloxone spray to formulary
SCIENTURE Secures Formulary Coverage for REZENOPY™ with a Large National Health Plan and Expands Commercial Team
GlobeNewswire  ·  06-09
SCIENTURE Secures Formulary Coverage for REZENOPY™ with a Large National Health Plan and Expands Commercial Team
Scienture wins US patent for REZENOPY naloxone nasal spray, protection through 2041
Reuters  ·  06-02
Scienture wins US patent for REZENOPY naloxone nasal spray, protection through 2041
Scienture Receives U.S. Patent Covering Rezenopy™ (Naloxone Hcl) Nasal Spray 10 Mg, Strengthening Intellectual Property Protection Through 2041
THOMSON REUTERS  ·  06-02
Scienture Receives U.S. Patent Covering Rezenopy™ (Naloxone Hcl) Nasal Spray 10 Mg, Strengthening Intellectual Property Protection Through 2041
SCIENTURE Receives U.S. Patent Covering REZENOPY™ (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 2041
GlobeNewswire  ·  06-02
SCIENTURE Receives U.S. Patent Covering REZENOPY™ (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 2041

Introduction

Company Name.
Scienture Holdings, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
TRxADE HEALTH, Inc. operates as a health services IT company in the United States. The company focuses on digitalizing the retail pharmacy experience by optimizing drug procurement, prescription journey, and patient engagement. It operates the TRxADE drug procurement marketplace, which offers price transparency, purchasing capabilities, and other value-added services; and offers patient centric telehealth services under the Bonum Health brand name. The company was formerly known as Trxade Group, Inc. and changed its name to TRxADE HEALTH, Inc. in June 2021. TRxADE HEALTH, Inc. is based in Lutz, Florida.
Issue price:
--